Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 May 4;15(5):e0223344. doi: 10.1371/journal.pone.0223344

Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD-18Co human colon fibroblast cells

Huan Huan Tan 1, Noel Francis Thomas 2, Salmaan Hussain Inayat-Hussain 3,4, Kok Meng Chan 1,*
Editor: Irina V Lebedeva5
PMCID: PMC7197815  PMID: 32365104

Abstract

Stilbenes are a group of chemicals characterized with the presence of 1,2-diphenylethylene. Previously, our group has demonstrated that synthesized (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) possesses potential chemopreventive activity specifically inducing NAD(P)H:quinone oxidoreductase 1 (NQO1) protein expression and activity. In this study, the cytoprotective effects of BK3C231 on cellular DNA and mitochondria were investigated in normal human colon fibroblast, CCD-18Co cells. The cells were pretreated with BK3C231 prior to exposure to the carcinogen 4-nitroquinoline 1-oxide (4NQO). BK3C231 was able to inhibit 4NQO-induced cytotoxicity. Cells treated with 4NQO alone caused high level of DNA and mitochondrial damages. However, pretreatment with BK3C231 protected against these damages by reducing DNA strand breaks and micronucleus formation as well as decreasing losses of mitochondrial membrane potential (ΔΨm) and cardiolipin. Interestingly, our study has demonstrated that nitrosative stress instead of oxidative stress was involved in 4NQO-induced DNA and mitochondrial damages. Inhibition of 4NQO-induced nitrosative stress by BK3C231 was observed through a decrease in nitric oxide (NO) level and an increase in glutathione (GSH) level. These new findings elucidate the cytoprotective potential of BK3C231 in human colon fibroblast CCD-18Co cell model which warrants further investigation into its chemopreventive role.

1. Introduction

Cancer-related mortality has increased tremendously and is expected to further increase despite emerging medical improvements [1]. The global incidence of cancer is estimated to have risen in 2018 with colorectal cancer being the third most commonly diagnosed cancer and is ranked second in terms of mortality due to poor prognosis worldwide [2]. In Malaysia, cancer is the third most common cause of death after cardiovascular diseases and respiratory diseases. According to Malaysia National Cancer Registry (MNCR) Report 2007–2011, colorectal cancer is the second most common cancer [3].

Advances in costly surgical and medical therapies for primary and metastatic colorectal cancer have had limited impact on cure rates and long-term survival [4,5]. The shift of momentum towards chemoprevention is the result of several observations. These include local recurrences after surgery, treatment-induced long-term complications, chemotherapy-induced adverse effects, as resistance to chemotherapy due to multidrug resistance phenotypes and tumour heterogeneity [68].

Chemopreventive approaches have effectively decreased cancer incidence rates such as for lung cancer and cervical cancer [2]. The cancer chemoprevention approach exploits nontoxic natural or synthetic pharmacological agents to prevent, block or reverse the multistep processes of carcinogenesis [9,10]. Chemopreventive agents inhibit the invasive development of cancer by affecting the three defined stages of carcinogenesis namely initiation, promotion and progression which are induced by carcinogens through genetic and epigenetic mechanisms [11,12].

Exposure of cells to carcinogens causes DNA mutation and leads to accumulation of additional genetic changes through sustained cell proliferation. This rapid and irreversible process is known as tumour initiation, the first stage of carcinogenesis. Tumour promotion, which is referred to as the lengthy and reversible second stage of carcinogenesis, involves the selective clonal expansion of initiated cells to produce preneoplastic lesions which enables additional mutations to accumulate. The final stage of carcinogenesis, tumour progression, involves neoplastic transformation after accumulating chromosomal aberrations and karyotypic instability resulting in metastatic malignancy [13,14].

Altered cellular redox status and disrupted oxidative homeostasis play key roles in cancer development by enhancing DNA damage and modifying key cellular processes such as cell proliferation and apoptosis [15]. Oxidative/nitrosative stress is the result of disequilibrium between reactive oxygen species (ROS)/reactive nitrogen species (RNS) and antioxidants [16]. If oxidative/nitrosative stress persists, this may lead to modification of signal transduction and gene expression, which in turn may lead to mutation, transformation and progression of cancer [17,18].

Stilbenes are produced in the skin, seeds, leaves and sapwood of a wide variety of plant species including dicotyledon angiosperms such as grapevine (Vitis vinifera), peanut (Arachis hypogaea) and Japanese knotweed (Fallopia Japonica); monocotyledons like sorghum (Sorghum bicolor) and gymnosperms such as several Pinus and Picea species [1921]. They are a well-known class of naturally occurring phytochemicals acting as antifungal phytoalexins, providing protection against UV light exposure and also involved in bacterial root nodulation and coloration [19,2224]. These compounds bear the core structure of 1,2-diphenylethylene in which two benzene rings are separated by an ethanyl or ethenyl bridge [25].

Despite being known as plant defense compounds, stilbenes have an enormous diversity of effects on biological and cellular processes applicable to human health, particularly in chemoprevention. Resveratrol, as the biosynthetic precursor of most oligostilbenoids, has been known to possess a myriad of biological activities such as anticancer, antioxidant, anti-aging, antimicrobial, cardioprotection, anti-diabetes, anti-obesity, and anti-inflammation [2633]. However, low water solubility and poor bioavailability are the major setbacks to the exploitation of these biological activities [34,35].

Our group has previously demonstrated that synthetic stilbene BK3C231 (Fig 1) potently induced antioxidant gene NQO1 as a detoxifying mechanism in human embryonic hepatocytes, WRL-68 cells [36]. Therefore in this study, we propose to elucidate the cytoprotective effects of BK3C231 using normal human colon fibroblast CCD-18Co cells. We anticipate this study will build a strong base and accelerate the development of BK3C231 as a potential drug for chemoprevention.

Fig 1. Chemical structure of BK3C231 [36].

Fig 1

2. Materials and methods

2.1 Test compounds

(E)-N-(2-(3, 5-Dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) was synthesized and contributed by Dr. Noel Francis Thomas and Dr. Kee Chin Hui from Department of Chemistry, Faculty of Science, University of Malaya (Kuala Lumpur, Malaysia). 4-Nitroquinoline 1-oxide (4NQO) (Cas. No: 56-57-5, ≥98% purity) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock solution of BK3C231 at 100mM and 4NQO at 25mg/mL were prepared by dissolving the compounds in solvent dimethyl sulfoxide (DMSO; Thermo Fisher Scientific, Waltham, MA, USA).

2.2 Cell culture

The normal human colon fibroblast CCD-18Co cell line (ATCC CRL-1459) was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). CCD-18Co cells were grown in Minimum Essential Medium (MEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Biowest, Nuaillé, France) and 1% 100x Antibiotic-Antimycotic solution (Nacalai Tesque, Kyoto, Japan). All cells were between passages 3–5 for all experiments and maintained at 37°C with 5% CO2.

2.3 MTT cytotoxicity assay

CCD-18Co cells were seeded in 96-well microplate (Nest Biotechnology, Jiangsu, China) at the concentration of 5 x 104 cells/mL in a volume of 200 μL per well. The seeded cells were incubated under 5% CO2 at 37°C for 24 hours prior to respective compound treatments at different timepoints. After incubation, 20 μL of Thiazolyl Blue Tetrazolium Bromide (MTT; Sigma-Aldrich, St. Louis, MO, USA) solution (5mg/mL in PBS) was added to the treated cells and further incubated for 4 hours at 37°C. Subsequently, the total medium in each well was discarded and the crystalline formazan was solubilised using 200 μL DMSO. For complete dissolution, the plate was incubated for 15 minutes followed with gentle shaking for 5 minutes. The cytotoxicity of BK3C231 and 4NQO was assessed by measuring the absorbance of each well at 570 nm using iMarkTM microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). Mean absorbance for each compound concentration was expressed as a percentage of vehicle control absorbance and plotted versus compound concentration. The inhibitory concentration that kills 50% of cell population (IC50) represents the compound concentration that reduced the mean absorbance at 570 nm to 50% of those in the vehicle control wells. [dx.doi.org/10.17504/protocols.io.bdp6i5re]

2.4 Alkaline comet assay

Seeded cells (5 x 104 cells/mL) in 6-well plate (Nest Biotechnology, Jiangsu, China) were pretreated with BK3C231 at 6.25 μM, 12.5 μM, 25 μM and 50 μM for 2 hours prior to 4NQO treatment at 1 μM for 1 hour. Following incubation, detached cells in the medium were collected and added back to trypsinised cells. Then, the cell suspension was transferred to the tube for centrifugation (450 x g/5 minutes at 4°C). The supernatant was removed and pellet was washed with Ca2+- and Mg2+-free PBS and re-centrifuged. The pellets left at the bottom were mixed thoroughly with 80 μl of 0.6% w/v LMA (Sigma-Aldrich, St. Louis, MO, USA). The mixture was then pipetted onto the hardened 0.6% w/v NMA (Sigma-Aldrich, St. Louis, MO, USA) as the first layer gel on the slide. Cover slips were placed to spread the mixture and slides were left on ice for LMA to solidify. Following removal of the cover slips, the embedded cells were lysed in a lysis buffer containing 2.5M NaCl (Merck Milipore, Burlington, MA, USA), 1 mM Na2EDTA (Sigma-Aldrich, St. Louis, MO, USA), 10 mM Tris (Bio-Rad Laboratories, Hercules, CA, USA) and 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) overnight at 4°C. After lysis, the slides were soaked in electrophoresis buffer solution for 20 minutes for DNA unwinding before electrophoresis at 300 mA, 25V for 20 minutes. Subsequently, the slides were rinsed with neutralising buffer for 5 minutes and stained with 30 μL of 50 μg/mL ethidium bromide (EtBr; Sigma-Aldrich, St. Louis, MO, USA) solution. Slides were left overnight at 4°C before analyzing with Olympus BX51 fluorescence microscope (Tokyo, Japan) equipped with 590 nm filter. DNA damage scoring was performed on 50 cells per slide whereby tail moment representing the product of tail length and fraction of total DNA in tail was quantified using Comet ScoreTM software (TriTek Corp, Sumerduck, VA, USA). [dx.doi.org/10.17504/protocols.io.bdqgi5tw]

2.5 Cytokinesis-block micronucleus (CBMN) assay

Seeded cells (5 x 104 cells/mL) in 6-well plate were pretreated with BK3C231 at 6.25 μM, 12.5 μM, 25 μM and 50 μM for 2 hours prior to 4NQO treatment at 1 μM for 2 hours. After incubation, cells were treated with 4.5 μg/mL Cytochalasin B (Sigma-Aldrich, St. Louis, MO, USA) for 24 hours to block cytokinesis. The cells were then harvested and centrifuged (450 x g/5 minutes at 4°C). The supernatant was removed and pellet was resuspended with 300 μL of 0.075M KCl solution for 5 minutes. The cells were then fixed with Carnoy’s solution consisting of acetic acid (Sigma-Aldrich, St. Louis, MO, USA) and methanol (HmbG Chemicals, Hamburg, Germany) prepared at the ratio of 1:3 and spreaded on glass slides which were placed on a slide warmer. The slides were dried overnight and stained with 30 μL of 20 μg/mL acridine orange (AO; Sigma-Aldrich, St. Louis, MO, USA) prior to fluorescence microscopic observation. The number of viable mononucleated, binucleated and multinucleated cells per 500 cells were scored to derive Nuclear Division Index (NDI) and frequency of micronucleus in 1,000 binucleated cells was measured. [dx.doi.org/10.17504/protocols.io.bdqhi5t6]

2.6 Mitochondrial membrane potential (ΔΨm), mitochondrial mass and ROS assessment

The treated cells (5 x 104 cells/mL) were collected by centrifugation (450 x g/5 minutes at 4°C). The supernatant was discarded and pellet was resuspended with 1 mL fresh prewarmed FBS-free MEM with addition of 1 μL of 50 μM tetramethylrhodamine ethyl ester (TMRE; Thermo Fisher Scientific, Waltham, MA, USA), 5 mM nonyl acridine orange (NAO; Sigma-Aldrich, St. Louis, MO, USA), 10 mM hydroethidine (HE; Thermo Fisher Scientific, Waltham, MA, USA) or 10 mM 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA; Thermo Fisher Scientific, Waltham, MA, USA). The cells stained with TMRE or NAO were incubated for 15 minutes at 37°C whereas cells stained with HE and DCFH-DA were incubated for 30 minutes at 37°C in the dark. After incubation, the cells were centrifuged (450 x g/5 minutes at 4°C) and pellet was washed with 1 mL chilled PBS solution. The supernatant was discarded and 500 μL of chilled PBS was used to resuspend the pellets. The stained cell suspension was transferred to flow tubes and analyzed using FACSCanto II Flow Cytometer (BD Biosciences, San Jose, CA, USA). [dx.doi.org/10.17504/protocols.io.bdqii5ue; dx.doi.org/10.17504/protocols.io.bdqji5un; dx.doi.org/10.17504/protocols.io.bdqki5uw; dx.doi.org/10.17504/protocols.io.bdqmi5u6]

2.7 Intracellular Nitric Oxide (NO) assessment using BD Pharmingen orange nitric oxide (NO) probe staining

The seeded cells (5 x 104 cells/mL) were pre-stained with 1 μL Orange NO probe (BD Biosciences, San Jose, CA, USA) per 500 μL cell suspension for 30 minutes. The cells were then pretreated with BK3C231 at 50 μM and positive control, resveratrol (Sigma-Aldrich, St. Louis, MO, USA) at 25 μM for 2 hours, 4 hours, 6 hours, 12 hours and 24 hours prior to 4NQO treatment at 1 μM for 1 hour. The stained and treated cells were centrifuged (450 x g/5 minutes at 4°C) and pellet was washed with 1 mL chilled PBS solution. The supernatant was discarded and 500 μL of chilled PBS was used to resuspend the pellets. The stained cell suspension was transferred to flow tubes and analyzed using FACSCanto II Flow Cytometer (BD Biosciences, San Jose, CA, USA). [dx.doi.org/10.17504/protocols.io.bdqni5ve]

2.8 Extracellular Nitric Oxide (NO) assessment using griess reagent

CCD-18Co cells were seeded in culture dish (60 x 15 mm) at the concentration of 5 x 104 cells/mL. The seeded cells were incubated under 5% CO2 at 37°C for 24 hours. The cells were then pretreated with BK3C231 at 50 μM and positive control, resveratrol at 25 μM for 2 hours, 4 hours, 6 hours, 12 hours and 24 hours prior to 4NQO treatment at 1 μM for 1 hour. Subsequently, 100 μL of culture medium from each sample was collected and mixed with the same volume of Griess reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% N-(1-naphthyl)ethylenediamine (NNED) hydrochloride in distilled water, Merck Milipore, Burlington, MA, USA) in 96-well microplate. Absorbance of the mixture in each well was determined at 570 nm using iMarkTM microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). The concentration of nitrite accumulated in the culture was determined in comparison to the sodium nitrite standards. [dx.doi.org/10.17504/protocols.io.bdqpi5vn]

2.9 Glutathione (GSH) assessment using ellman’s reagent

The treated cells (5 x 104 cells/mL) were detached, collected and centrifuged (450 x g/5 minutes at 4°C). The supernatant was discarded and pellet was resuspended in 100 μL ice-cold lysis buffer (50 mM K2HPO4, 1 mM EDTA, pH 6.5 and 0.1% v/v Triton X-100, Sigma-Aldrich, St. Louis, MO, USA). The cells were incubated on ice for 15 minutes with gentle tapping from time to time. The crude lysates were cleared by centrifugation (10000 x g/15 minutes at 4°C). At this point, the lysates were used immediately or stored at -80°C for a day or two. Then, 50 μl of lysates and GSH standards (two fold dilution from 1.25 mM to 0 mM dissolved in reaction buffer consisting of 0.1 M Na2HPO4.7H2O and 1 mM EDTA, pH 6.5, Sigma-Aldrich, St. Louis, MO, USA) were pipetted into designated wells in a 96-well microplate. After adding 40 μl of reaction buffer (0.1 M Na2HPO4.7H2O and 1 mM EDTA, pH 8), 10 μl of 4 mg/ml 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB; Sigma-Aldrich, St. Louis, MO, USA) in reaction buffer pH 8 was added to wells containing samples and standards. The plate was incubated for 15 minutes at 37°C. Absorbance of each well was measured at 405 nm using iMarkTM microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). The concentration of free thiols in samples was calculated based on GSH standard and expressed as nmol/mg protein after protein concentration was quantified using Bradford’s method. [dx.doi.org/10.17504/protocols.io.bdqqi5vw]

2.10 Statistical analysis

The data are expressed as the mean ± standard error of mean (S.E.M.) from at least three independent experiments. The statistical significance was evaluated using one-way ANOVA with the Tukey post hoc test used to assess the significance of differences between multiple treatment groups. Differences were considered statistically significant with a probability level of p<0.05.

3. Results

3.1 Cytotoxic assessment of BK3C231 and 4NQO

The non-cytotoxic concentrations of BK3C231 and 4NQO were determined using MTT cytotoxicity assay. BK3C231 did not show evidence of cytotoxicity up to 50 μM treatment, however an IC50 value of 99 μM was observed (Fig 2A). Therefore a series of BK3C231 concentrations ranging from 6.25 μM till 50 μM was used for subsequent experiments. On the other hand, 4NQO treatment exerted no cytotoxicity at 1 hour. However, reduction in cell viability was significant with IC50 values observed starting from 2 hours till 24 hours (Fig 2B). Hence, 4NQO concentration at 1 μM was selected to induce genotoxicity and mitochondrial toxicity in subsequent experiments as used by previous studies as well [37,38]. Interestingly, in comparison to 4NQO-treated cells whereby cell viability greatly reduced especially at higher concentrations, BK3C231 was able to suppress 4NQO-induced cytotoxicity by increasing cell viability up to 8-fold with no IC50 value observed (Fig 2C).

Fig 2. Effect of BK3C231 and 4NQO on the viability of CCD-18Co cells as assessed by MTT assay.

Fig 2

(A) Cells were treated with BK3C231 from 6.25 μM till 100 μM for 24h. An IC50 value of 99 μM was observed. (B) Cells were treated with 4NQO from 3.125 μM till 50 μM for 1h (no IC50 value), 2h (IC50 value was 41 μM), 4h (IC50 value was 24 μM), 12h (IC50 value was 34 μM) and 24h (IC50 value was 13 μM). (C) Cells were pretreated with BK3C231 at 50 μM for 2h prior to 4NQO treatment from 3.125 μM till 50 μM for subsequent 22h (no IC50 value) in comparison to BK3C231-treated (no IC50 value) and 4NQO-treated cells (IC50 value was 13 μM). Each data point was obtained from three independent experimental replicates and expressed as mean ± SEM of percentage of cell viability. * p<0.05 against negative control.

3.2 BK3C231 protection against 4NQO-induced DNA microlesions

Significant DNA damage as indicated by the comet tail which represents DNA strand breaks can be observed in cells treated only with 4NQO. Untreated control cells and BK3C231-treated cells showed intact round nuclear DNA and no DNA strand break was observed at all treated concentrations (Fig 3A). There was also a decrease in comet tail in cells pretreated with BK3C231 when compared with that of cells treated only with 4NQO (Fig 3B). This was further confirmed by quantification of tail moments obtained from comet scoring. Tail moment increased significantly up to 48-fold in 4NQO-treated cells at 28.79 ± 1.02 (p<0.05) over control and BK3C231-treated cells ranging from 0.59 ± 0.11 to 0.68 ± 0.06 (Fig 3C). On the other hand, BK3C231 pretreatment showed a 0.8-fold decrease of 4NQO-induced DNA strand breaks in a concentration-dependent manner, significantly at 50 μM with a tail moment value of 7.21 ± 0.34 (p<0.05) (Fig 3D).

Fig 3. DNA microlesion assessment in CCD-18Co cells using alkaline comet assay.

Fig 3

(A) Fluorescence microscopic images with EtBr staining of untreated cells (i), cells treated with BK3C231 at 6.25 μM (ii), 12.5 μM (iii), 25 μM (iv) and 50 μM (v) for 24h and cells treated with 4NQO at 1 μM for 1h (vi). (B) Fluorescence microscopic images of untreated cells (i), cells treated with BK3C231 at 6.25 μM (ii), 12.5 μM (iii), 25 μM (iv) and 50 μM (v) for 2h prior to 4NQO induction at 1 μM for 1h and cells treated with 4NQO at 1 μM for 1h (vi). (C) Screening for DNA damage expressed as tail moment in cells treated respectively with BK3C231 from 6.25 μM till 50 μM for 24h and 4NQO at 1 μM for 1h. (D) Cells were pretreated with BK3C231 from 6.25 μM till 50 μM for 2h prior to 4NQO induction at 1 μM for 1h. Each data was obtained from three independent experimental replicates and each data point in (C) and (D) was expressed as mean ± SEM of tail moment. * p<0.05 against negative control, CON (C) and # p<0.05 against positive control, 4NQO only (D).

3.3 Inhibition of 4NQO-induced DNA macrolesions by BK3C231

The protective role of BK3C231 against 4NQO-induced micronucleus formation was assessed using CBMN assay (Fig 4A). In untreated control cells, a micronucleus frequency level as low as 0.23 ± 0.03 was observed. Cells treated with 4NQO significantly demonstrated up to 93-fold increase in frequency of micronucleus in binucleated cells at 21.56 ± 1.36 (p<0.05). However, pretreatment of cells with BK3C231 was shown to cause a maximum of 0.8 fold decrease of 4NQO-induced micronucleus formation in a concentration-dependent manner, significantly at 25 μM with a frequency level of 6.58 ± 0.52 and 50 μM with a frequency level of 3.80 ± 0.47 (p<0.05) (Fig 4B). In addition, the NDI values measured in control, 4NQO-treated cells and BK3C231-treated cells were 1.78 ± 0.01, 1.68 ± 0.03 and 1.79 ± 0.01 respectively. As for cells pretreated with BK3C231 prior to 4NQO induction, the average NDI value measured was 1.72 ± 0.01 (Table 1). All NDI values obtained in this assay indicated normal cell proliferation [39].

Fig 4. DNA macrolesion assessment in CCD-18Co cells using CBMN assay.

Fig 4

(A) Fluorescence microscopic images with acridine orange staining of mononucleated cell (i), binucleated cell (ii) and binucleated cell with micronucleus (iii). Cellular nucleus was stained green while cytoplasm was stained orange in this assay. (B) Cells were pretreated with BK3C231 from 6.25 μM till 50 μM for 2h prior to 4NQO induction at 1 μM for 2h. Each data point was obtained from three independent experimental replicates and expressed as mean ± SEM of frequency of micronucleus in binucleated cells. * p<0.05 against positive control, 4NQO only.

Table 1. NDI values in untreated control cells, BK3C231-treated cells, 4NQO-treated cells and cells pretreated with BK3C231 prior to 4NQO induction.

Treatment NDI value
Untreated control 1.78 ± 0.01
4NQO 1 μM 1.68 ± 0.03
BK3C231 50 μM 1.79 ± 0.01
BK3C231 6.25 μM + 4NQO 1 μM 1.74 ± 0.01
BK3C231 12.5 μM + 4NQO 1 μM 1.70 ± 0.01
BK3C231 25 μM + 4NQO 1 μM 1.74 ± 0.01
BK3C231 50 μM + 4NQO 1 μM 1.71 ± 0.01

NDI, nuclear index division; μM, micromolar; 4NQO, 4-Nitroquinoline 1-oxide.

3.4 Cytoprotective role of BK3C231 in 4NQO-induced mitochondrial damages

The cytoprotective role of BK3C231 was further investigated at the mitochondrial level through flow cytometric assessment of ΔΨm loss using TMRE staining. Significant loss of ΔΨm (p<0.05) as indicated by a 1.2-fold increase of TMRE-negative cells from 15.63 ± 1.09% in control cells to 34.77 ± 1.29% in 4NQO-treated cells was observed. However, BK3C231 pretreatment was shown to reduce the amount of TMRE-negative cells significantly to 22.13 ± 2.51% (p<0.05) at 50 μM, thereby protecting the cells against 4NQO-induced ΔΨm loss (Fig 5A). Positive control, resveratrol also decreased the amount of TMRE-negative cells significantly to 24.07 ± 0.22% (p<0.05) at 25 μM.

Fig 5. Assessment of mitochondrial toxicity in CCD-18Co cells.

Fig 5

(A) Flow cytometric analysis of ΔΨm level using TMRE staining. (B) Flow cytometric analysis of cardiolipin level using NAO staining. Cells were pretreated with BK3C231 from 6.25 μM till 50 μM and resveratrol (res) at 25 μM for 2h prior to 4NQO induction at 1 μM for 2h. Each data point was obtained from three independent experimental replicates and expressed as mean ± SEM of TMRE- or NAO-negative cells (%). * p<0.05 against positive control, 4NQO only.

In a bid to further establish the protective role of BK3C231 in mitochondria, cardiolipin level was assessed through flow cytometric analysis using NAO staining. Our study demonstrated significant cardiolipin loss (p<0.05) as indicated by a 2.8-fold increase of NAO-negative cells from 5.07 ± 0.52% in control cells to 19.33 ± 0.94% in 4NQO-treated cells. However, BK3C231 pretreatment was shown to induce up to 0.4-fold decrease of 4NQO-induced cardiolipin loss in a concentration-dependent manner (Fig 5B). Positive control, resveratrol also reduced the amount of TMRE-negative cells significantly to 12.83 ± 0.13% (p<0.05) at 25 μM.

3.5 4NQO-induced DNA and mitochondrial damages independent of ROS production

Flow cytometric assessment of intracellular ROS namely superoxide and hydrogen peroxide levels using HE and DCFH-DA staining was performed to determine the role of ROS in 4NQO-induced DNA and mitochondrial damages. Interestingly, as shown in Fig 6A and 6B, there were no inductions of superoxide and hydrogen peroxide levels in 4NQO-treated cells as compared to control cells. Hydroquinone (HQ), which was used as positive control, had significantly increased ROS level in CCD-18Co cells (p<0.05). This suggested that ROS was not involved in DNA and mitochondrial damages caused by 4NQO, also leading to indication that neither cytoplasm nor mitochondria played a role in ROS production in 4NQO-treated cells. In addition, BK3C231 demonstrated potential as antioxidant by inhibiting HQ-induced ROS production.

Fig 6. Assessment of ROS production in CCD-18Co cells.

Fig 6

(A) Flow cytometric analysis of superoxide level using HE staining. (B) Flow cytometric analysis of hydrogen peroxide level using DCFH-DA staining. Cells were treated with BK3C231 at 50 μM for 24h and 4NQO at 1 μM for 1h. HQ treatment at 50 μM for 2h was used as positive control in this assay. Cells were also pretreated with BK3C231 at 50 μM for 24h prior to HQ induction at 50 μM for 2h. Each data point was obtained from three independent experimental replicates and expressed as mean ± SEM of HE- or DCF-stained cells (%). * p<0.05 against negative control, CON.

3.6 Inhibition of 4NQO-induced nitrosative stress by BK3C231

Intracellular nitric oxide (NO) level was assessed using BD Pharmingen Orange NO Probe staining whereas extracellular NO level was assessed using Griess assay to determine the involvement of RNS in 4NQO-induced DNA and mitochondrial damages. Our study demonstrated a significant 0.98-fold increase of intracellular NO level, 15.7 ± 0.19% and 2.4-fold increase of extracellular NO level, 5.15 ± 0.17 μM (p<0.05) in 4NQO-treated cells over control cells, at 7.63 ± 0.19% and 1.51 ± 0.26 μM respectively, thereby demonstrating the involvement of NO in 4NQO-induced DNA and mitochondrial damages. Moreover, both BK3C231 and positive control, resveratrol significantly inhibited 4NQO-induced NO production from as early as 2 hours up till 24 hours of pretreatment (p<0.05) and were able to restore NO level back to basal level at 24 hours of pretreatment (Fig 7A and 7B).

Fig 7. Nitrosative stress assessment in CCD-18Co cells.

Fig 7

(A) Determination of intracellular NO level using Orange NO probe staining. (B) Determination of extracellular NO level using Griess assay. (C) Measurement of intracellular GSH level using Ellman’s reagent. Cells were pretreated with BK3C231 at 50 μM and resveratrol (res) at 25 μM for 2h, 4h, 6h, 12h and 24h prior to 4NQO induction at 1 μM for 1h. Each data point was obtained from three independent experimental replicates and expressed as mean ± SEM of orange NO probe-stained cells (%), NO level and concentration of free thiol. * p<0.05 against positive control, 4NQO only.

In addition to that, antioxidant GSH level was assessed using Ellman’s reagent. 4NQO-treated cells showed a reduced GSH level at 194.70 ± 23.83 nmol/mg as compared to untreated control cells at 245.96 ± 12.44 nmol/mg (Fig 7C). Overall, the simultaneous increase in NO level and decrease in GSH level by 4NQO further confirmed the involvement of nitrosative stress in 4NQO-induced DNA and mitochondrial damages. However, no induction of GSH level was observed in cells pretreated with BK3C231 for 2 hours, 4 hours, 6 hours and 12 hours. BK3C231 was only able to significantly increase GSH level, 313.97 ± 27.83 nmol/mg (p<0.05) at 24 hours of pretreatment as compared to that of 4NQO-treated cells (Fig 7C). This suggested that BK3C231 inhibited 4NQO-induced nitrosative stress through early reduction of NO production and late induction of GSH level in CCD-18Co cells.

4. Discussion

Epidemiological studies have shown that consumption of fruits particularly rich in stilbenes led to a reduced risk of colorectal cancer, which is one of the most commonly diagnosed cancers worldwide [40,41]. Furthermore, cytoprotection of DNA and mitochondrial function limits the occurrence of cancer. Since DNA is the repository of hereditary material and genetic information in every living cell, the maintenance of its stability is pivotal as unrepaired DNA damage caused by diverse assaults from the environment, nutrition and natural cellular processes lead to cancer [42,43]. As for mitochondria, impairments and alterations of mitochondrial structure and functions, including morphology and redox potential, are associated with cancer transformation and have been frequently reported in human cancers [4446]. In agreement with this, our study showed that BK3C231 was able to inhibit 4NQO-induced cytotoxicity as well as protect against DNA damage and mitochondrial dysfunction in the normal human colon fibroblast CCD-18Co cell line.

Firstly, we sought to understand the carcinogenic actions of 4NQO. Studies have demonstrated that 4NQO elicited carcinogenicity through its proximate carcinogenic metabolite namely 4-hydroxyaminoquinoline 1-oxide (4HAQO) produced by the enzymatic four-electron reduction of 4NQO’s nitro group [47,48]. Being a potent chemical carcinogen and as a UV-mimetic agent, 4NQO is often used as positive control in various genotoxicity studies due to its well characterized metabolic processes [49]. As a result of a study by Brüsehafer et al. [50], it was reported that 4NQO predominantly induces mutagenicity more than clastogenicity and that the latter depends on cell types, our study has proved that 4NQO is a significant cause of DNA damage via DNA strand breaks and chromosomal damage via micronucleus formation. Our study was also in agreement with previous studies which demonstrated that 4NQO caused damage to mitochondrial membrane as characterized by loss of mitrochondrial membrane potential (ΔΨm) and cardiolipin [51].

As 4HAQO’s carcinogenic effect is mainly based on DNA adduct formation, our study investigated 4NQO’s other carcinogenic mechanism of action through generation of ROS and RNS and its involvement in the cytoprotective role of BK3C231 [5254]. Interestingly, our study which revealed no superoxide and hydrogen peroxide production by 4NQO at 1 μM for 1 hour in CCD-18Co cells contradicts the study by Arima et al. [37] who reported ROS formation in human primary skin fibroblast by 4NQO using the same treatment concentration and timepoint. The discrepancy is likely due to the difference in the origin of fibroblast used. Hence, our study is the first to elucidate such findings on 4NQO mechanism which has never been shown in other studies thus far.

In addition, our study demonstrated an increased NO level and a depleted GSH level by 4NQO. This is possibly due to formation of 4NQO-GSH conjugates leading to generation of nitrite, a stable end product of NO, which inactivated γ-glutamylcysteine synthase and therefore suppressed intracellular synthesis of GSH [37,5456]. Our data was also in agreement with previous studies that NO could be the main culprit in 4NQO-induced DNA and mitochondrial damages in CCD-18Co cells as NO has been demonstrated to induce genotoxicity and damage to mitochondria via multiple mechanisms directly or indirectly [57,58]. Moreover, the concurrent increase in NO level and decrease in GSH level postulates the occurrence of nitrosative stress which may contribute to 4NQO-induced DNA and mitochondrial damage [59,60].

More importantly, BK3C231 was shown in our study to protect against 4NQO-induced DNA and mitochondrial damages by decreasing DNA strand breaks and micronucleus formation as well as reducing loss of mitochondrial membrane potential (ΔΨm) and cardiolipin (Fig 8). Our study further revealed that BK3C231 exerted these cytoprotective effects in CCD-18Co cells by suppressing 4NQO-induced nitrosative stress through reduction in NO level and late upregulation of GSH level. Furthermore, inhibition of HQ-induced ROS production by BK3C231 as demonstrated in this study corroborates the potential of BK3C231 as an antioxidant. The role of stilbene derivatives as potential antioxidants has been demonstrated in several studies involving for example resveratrol, a well-known stilbenoid, which attenuates nitrosative stress in the small intestine of rats [61]. Piceatannol and isorhapontigenin, which are natural occurring stilbenes, have also been demonstrated to scavenge NO and nitrogen dioxide (NO2) radicals as well as increasing GSH/GSSG ratio [62,63]. Therefore, we have included resveratrol, which is under the same stilbene family as BK3C231, as the positive control in this study which supported the BK3C231 findings and were consistent with previous studies which had reported the protective effects of resveratrol on mitochondrial function as well as its role in NO suppression and GSH induction [6468].

Fig 8. Schematic representation of BK3C231-induced cytoprotection against 4NQO damage in CCD-18Co human colon fibroblast cells.

Fig 8

4NQO caused DNA strand breaks and micronucleus formation as well as mitochondrial membrane potential (ΔΨm) and cardiolipin losses in CCD-18Co cells through NO formation. BK3C231 inhibited these 4NQO-induced DNA and mitochondrial damages by decreasing NO level and increasing GSH level.

Nitrosative stress is one of the most critical factors in multi-stage carcinogenesis with NO playing an important role in tumour biology and overproduction of NO can promote tumour growth [69]. Kee et al. [36] has reported the chemopreventive activity of BK3C231 involving upregulation of the detoxifying enzyme NQO1 due to the presence of methoxy and furan carboxamide groups. Therefore, it is possible that the presence and substitution pattern in relation to the methoxy group enables BK3C231 to act as an NO scavenger.

The Keap1-Nrf2 signaling pathway may also be involved in the depletion of NO level by BK3C231. The upstream Keap1-Nrf2 signaling pathway, which is a major regulator of phase II detoxification and cytoprotective genes, is postulated to be involved through upregulation of detoxifying enzymes which may lead to NO suppression [70]. Stilbene derivatives particularly resveratrol play a significant role in the activation of Nrf2-related gene transcription which induces expression of cytoprotective enzymes such as NQO1, glutathione S-transferase (GST), glutamate-cysteine ligase catalytic subunit (GCLC) and heme oxygenase-1 (HO-1) thus leading to protection against cancer [71]. Moreover, the increase in GSH as observed in this study can be attributed to the redox-sensitive Nrf2 activation [72,73].

Cytoprotection plays an important role in chemoprevention by suppressing the initiation stage of carcinogenesis. Cytoprotective mechanisms in response to DNA and mitochondrial damages by key causes of malignant transformation such as electrophile, oxidative stress and nitrosative stress represent a target for chemopreventive agent [74]. Our study has demonstrated the cytoprotective role of BK3C231, therefore it warrants further investigation of the chemopreventive role of BK3C231 in the Keap1-Nrf2 pathway which serves as both an important target thus provide significant protection of normal cells against carcinogenesis.

5. Conclusion

In conclusion, this study has provided a good insight into 4NQO-induced carcinogenicity in CCD-18Co cells. The demonstration of BK3C231 as a cytoprotective agent also served as a stepping stone for further elucidation of its chemopreventive potential against both genetic and epigenetic bases of cancer development. Based on our current findings in this study, we aim to reduce the gap between understanding molecular mechanism occurring in cancer carcinogenesis and instigating successful adoption of chemoprevention using BK3C231.

Acknowledgments

The authors would like to thank Dr. Kee Chin Hui, previously of the Department of Chemistry, Faculty of Science, University of Malaya for her contribution in the synthesis of compound BK3C231.

Data Availability

All relevant data are within the manuscript.

Funding Statement

This research was financially supported by Exploratory Research Grant Scheme (ERGS) from Kementerian Pendidikan Malaysia (Grant number: ERGS/1/2013/SKK03/UKM/02/1, URL: http://jpt.mohe.gov.my/portal/penyelidikan/mygrants) and Dana Impak Perdana (DIP) from Universiti Kebangsaan Malaysia (Grant number: DIP-2012-024, URL: http://research.ukm.my/) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Kuipers EJ, Rösch T, Bretthauer M. Colorectal cancer screening-optimizing current strategies and new directions. Nat Rev Clin Oncol. 2013; 10(3):130–142. 10.1038/nrclinonc.2013.12 [DOI] [PubMed] [Google Scholar]
  • 2.Saracci R, Wild CP. International Agency for Research on Cancer: the first 50 years, 1965–2015. Lyon (France): International Agency for Research on Cancer; 2015. [Google Scholar]
  • 3.Manan AA, Ibrahim Tamin NS, Abdullah NH, Abidin AZ, Wahab M 2016. Malaysian National Cancer Registry Report 2007–2011: Malaysia Cancer Statistics, Data and Figure. National Cancer Institute, Ministry of Health Malaysia; 2016; 1–202. [Google Scholar]
  • 4.Penny LK, Wallace HM. The challenges for cancer chemoprevention. Chem Soc Rev. 2015; 44(24):8836–8847. 10.1039/c5cs00705d [DOI] [PubMed] [Google Scholar]
  • 5.Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Primers. 2015; 1:15065 10.1038/nrdp.2015.65 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011; 12(6):575–582. 10.1016/S1470-2045(11)70097-3 [DOI] [PubMed] [Google Scholar]
  • 7.Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28):3499–3506. 10.1200/JCO.2012.42.8201 [DOI] [PubMed] [Google Scholar]
  • 8.Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014; 5:159 10.3389/fphar.2014.00159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sporn MB, Suh NJ. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer. 2002; 2(7): 537–543. 10.1038/nrc844 [DOI] [PubMed] [Google Scholar]
  • 10.Surh YJ, Na HK. NF-κB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr. 2008; 2(4): 313–317. 10.1007/s12263-007-0063-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Navasiyam N. Chemoprevention in experimental animals. Ann NY Acad Sci. 2011; 1215: 60–71. 10.1111/j.1749-6632.2010.05873.x [DOI] [PubMed] [Google Scholar]
  • 12.Shrotriya S, Agarwal R, Sclafani RA. A perspective on chemoprevention by resveratrol in head and neck squamous cell carcinoma. Adv Exp Med Biol. 2015; 815: 333–348. 10.1007/978-3-319-09614-8_19 [DOI] [PubMed] [Google Scholar]
  • 13.Barcellos-Hoff MH, Lyden D, Wang TC. The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer. 2013; 13(7): 511–518. 10.1038/nrc3536 [DOI] [PubMed] [Google Scholar]
  • 14.Kotecha R, Takami A, Luis Espinoza J. Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget. 2016; 7(32): 52517–52529. 10.18632/oncotarget.9593 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011; 9(171): 1–14. 10.1186/1479-5876-9-171 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kurutas EB. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state. Nutr J. 2016; 15(71): 1–22. 10.1186/s12937-016-0186-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82(1): 47–95. 10.1152/physrev.00018.2001 [DOI] [PubMed] [Google Scholar]
  • 18.Kruk J, Aboul-Enein HY. Reactive oxygen and nitrogen species in carcinogenesis: Implications of oxidative stress on the progression and development of several cancer types. Mini Rev Med Chem. 2017; 17(11): 904–919. 10.2174/1389557517666170228115324 [DOI] [PubMed] [Google Scholar]
  • 19.Langcake P, Pryce RJ. A new class of phytoalexins from grapevines. Experientia. 1977; 33(2): 151–152. 10.1007/bf02124034 [DOI] [PubMed] [Google Scholar]
  • 20.Chen RS, Wu PL, Chiou RYY. Peanut roots as a source of resveratrol. J Agric Food Chem. 2002; 50(6): 1665–1667. 10.1021/jf011134e [DOI] [PubMed] [Google Scholar]
  • 21.Parage C, Tavares R, Rety S, Baltenweck-Guyot R, Poutaraud A, Renault L, et al. Structural, functional, and evolutionary analysis of the unusually large stilbene synthase gene family in grapevine. Plant Physiol. 2012; 160(3): 1407–1419. 10.1104/pp.112.202705 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hart JH, Shrimpton DM. Role of stilbenes in resistance of wood to decay. Phytopathology. 1979; 69: 1138–1143. [Google Scholar]
  • 23.King RE, Bomser JA, Min DB. Bioactivity of resveratrol. Compr Rev Food Sci Food Safety. 2006; 5: 65–70. 10.1111/j.1541-4337.2006.00001.x [DOI] [Google Scholar]
  • 24.Watts KT, Lee PC, Schmidt-Dannert C. Biosynthesis of plant-specific stilbene polyketides in metabolically engineered Escherichia coli. BMC Biotechnol. 2006; 6:22 10.1186/1472-6750-6-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Inayat-Hussain SH, Thomas NF. Recent advances in the discovery and development of stilbenes and lactones in anticancer therapy. Expert Opin Ther Pat. 2004; 14(6): 819–835. 10.1517/13543776.14.6.819 [DOI] [Google Scholar]
  • 26.Jang MS, Cai LN, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275(5297): 218–220. 10.1126/science.275.5297.218 [DOI] [PubMed] [Google Scholar]
  • 27.Bhat KPL, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci. 2002; 957: 210–229. 10.1111/j.1749-6632.2002.tb02918.x [DOI] [PubMed] [Google Scholar]
  • 28.Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425(6954): 191–196. 10.1038/nature01960 [DOI] [PubMed] [Google Scholar]
  • 29.Mahady GB, Pendland SL, Chadwick LR. Resveratrol and red wine extracts inhibit the growth of CagA+ strains of Helicobacter pylori in vitro. Am J Gastroenterol. 2003; 98(6): 1440–1441. 10.1111/j.1572-0241.2003.07513.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Olson ER, Naugle JE, Zhang X, Bomser JA, Meszaros JG. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol. 2005; 288(3): 1131–1138. 10.1152/ajpheart.00763.2004 [DOI] [PubMed] [Google Scholar]
  • 31.Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin induced diabetic rats. Am J Physiol Endocrinol Metab. 2006; 290(6): 1339–1346. 10.1152/ajpendo.00487.2005 [DOI] [PubMed] [Google Scholar]
  • 32.Gomez-Zorita S, Tréguer K, Mercader J, Carpéné C. Resveratrol directly affects in vitro lipolysis and glucose transport in human fat cells. J Physiol Biochem. 2013; 69(3): 585–593. 10.1007/s13105-012-0229-0 [DOI] [PubMed] [Google Scholar]
  • 33.Zhou ZX, Mou SF, Chen XQ, Gong LL, Ge WS. Anti-inflammatory activity of resveratrol prevents inflammation by inhibiting NF-κB in animal models of acute pharyngitis. Mol Med Rep. 2018; 17(1): 1269–1274. 10.3892/mmr.2017.7933 [DOI] [PubMed] [Google Scholar]
  • 34.Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 2004; 24(5A): 2783–2840. [PubMed] [Google Scholar]
  • 35.Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004; 32(12): 1377–1382. 10.1124/dmd.104.000885 [DOI] [PubMed] [Google Scholar]
  • 36.Kee CH, Ariffin A, Awang K, Takeya K, Morita H, Hussain SI, et al. Challenges associated with the synthesis of unusual o-carboxamido stilbenes by the Heck protocol: Intriguing substituent effects, their toxicological and chemopreventive implications. Org Biomol Chem. 2010; 8(24): 5646–5660. 10.1039/c0ob00296h [DOI] [PubMed] [Google Scholar]
  • 37.Arima Y, Nishigori C, Takeuchi T, Oka S, Morimoto K, Utani A, et al. 4-Nitroquinoline 1-oxide forms 8-hydroxydeoxyguanosine in human fibroblasts through reactive oxygen species. Toxicol Sci. 2006; 91(2): 382–392. 10.1093/toxsci/kfj161 [DOI] [PubMed] [Google Scholar]
  • 38.Lan A, Li W, Liu Y, Xiong Z, Zhang X, Zhou S, et al. Chemoprevention of oxidative stress-associated oral carcinogenesis by sulforaphane depends on NRF2 and the isothiocyanate moiety. Oncotarget. 2016; 7(33): 53502–53514. 10.18632/oncotarget.10609 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ionescu ME, Ciocirlan M, Becheanu G, Nicolaie T, Ditescu C, Teiusanu AG, et al. Nuclear division index may predict neoplastic colorectal lesions. Maedica (Buchar). 2011; 6(3): 173–178. [PMC free article] [PubMed] [Google Scholar]
  • 40.Donaldson MS. Nutrition and cancer: A review of the evidence for an anti-cancer diet. Nutr J. 2004; 3: 19 10.1186/1475-2891-3-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Rimando AM, Suh N. Biological/Chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med. 2008; 74(13): 1635–1643. 10.1055/s-0028-1088301 [DOI] [PubMed] [Google Scholar]
  • 42.Clancy S. DNA Damage & Repair: Mechanisms for Maintaining DNA Integrity. Nature Education. 2008; 1(1): 103. [Google Scholar]
  • 43.McKenna DJ, McKeown SR, McKelvey-Martin VJ. Potential use of the comet assay in the clinical management of cancer. Mutagenesis. 2008; 23(3): 183–190. 10.1093/mutage/gem054 [DOI] [PubMed] [Google Scholar]
  • 44.Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005; 39: 359–407. 10.1146/annurev.genet.39.110304.095751 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Alirol E, Martinou JC. Mitochondria and cancer: is there a morphological connection? Oncogene. 2006; 25(34): 4706–4716. 10.1038/sj.onc.1209600 [DOI] [PubMed] [Google Scholar]
  • 46.Tokarz P, Blasiak J. Role of mitochondria in carcinogenesis. Acta Biochim Pol. 2014; 61(4):671–678. [PubMed] [Google Scholar]
  • 47.Nagao M, Sugimura T. Molecular biology of the carcinogen, 4-nitroquinoline 1-oxide. Adv Cancer Res. 1976; 23: 131–169. 10.1016/s0065-230x(08)60545-x [DOI] [PubMed] [Google Scholar]
  • 48.Kitano M. Host genes controlling the susceptibility and resistance to squamous cell carcinoma of the tongue in a rat model. Pathol Int. 2000; 50(5): 353–362. 10.1046/j.1440-1827.2000.01058.x [DOI] [PubMed] [Google Scholar]
  • 49.Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, et al. Single Cell Gel/Comet Assay: Guidelines for In Vitro and In Vivo Genetic Toxicology Testing. Environ Mol Mutagen. 2000; 35(3): 206–221. [DOI] [PubMed] [Google Scholar]
  • 50.Brüsehafer K, Manshian BB, Doherty AT, Zaïr ZM, Johnson GE, Doak SH, et al. The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency. Mutagenesis. 2016; 31(2): 171–180. 10.1093/mutage/gev069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Han H, Pan Q, Zhang B, Li J, Deng X, Lian Z, et al. 4NQO induced apoptosis via p53-dependent mitochondrial signaling pathway. Toxicology. 2007; 230(2–3): 151–163. 10.1016/j.tox.2006.11.045 [DOI] [PubMed] [Google Scholar]
  • 52.Tada M. Seryl-tRNA synthetase and activation of the carcinogen 4-nitroquinoline 1-oxide. Nature. 1975; 255(5508): 510–512. 10.1038/255510a0 [DOI] [PubMed] [Google Scholar]
  • 53.Kohda K, Kawazoe Y, Minoura Y, Tada M. Separation and identification of N4-(guanosin-7-yl)-4-aminoquinoline 1-oxide, a novel nucleic acid adduct of carcinogen 4-nitroquinoline 1-oxide. Carcinogenesis. 1991; 12(8): 1523–1525. 10.1093/carcin/12.8.1523 [DOI] [PubMed] [Google Scholar]
  • 54.Nunoshiba T, Demple B. Potent intracellular oxidative stress exerted by the carcinogen 4-nitroquinoline-N-oxide. Cancer Res. 1993; 53(14): 3250–3252. [PubMed] [Google Scholar]
  • 55.Stanley JS, Benson AM. The conjugation of 4-nitroquinoline 1-oxide, a potent carcinogen, by mammalian glutathione transferases. 4-Nitroquinoline 1-oxide conjugation by human, rat and mouse liver cytosols, extrahepatic organs of mice and purified mouse glutathione transferase isoenzymes. Biochem J. 1988; 256(1): 303–306. 10.1042/bj2560303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Han J, Stamler JS, Li HL, Griffith OW. Inhibition of gammaglutamylcysteine synthetase by S-nitrosylation. Biology of Nitric Oxide. 1996; 5: 114. [Google Scholar]
  • 57.Burney S, Caulfield JL, Niles JC, Wishnok JS, Tannenbaum SR. The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res. 1999; 424(1–2): 37–49. 10.1016/s0027-5107(99)00006-8 [DOI] [PubMed] [Google Scholar]
  • 58.Li CQ, Trudel LJ, Wogan GN. Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53. PNAS. 2002; 99(16): 10364–10369. 10.1073/pnas.162356399 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Squadrito GL, Pryor WA. Oxidative chemistry of nitric oxide: The roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med. 1998; 25(4–5): 392–403. 10.1016/s0891-5849(98)00095-1 [DOI] [PubMed] [Google Scholar]
  • 60.Zhao J. Interplay among nitric oxide and reactive oxygen species. A complex network determining cell survival or death. Plant Signal Behav. 2007; 2(6): 544–547. 10.4161/psb.2.6.4802 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Ferreira PEB, Beraldi EJ, Borges SC, Natali MRM, Buttow NC. Resveratrol promotes neuroprotection and attenuates oxidative and nitrosative stress in the small intestine in diabetic rats. Biomed Pharmacother. 2018; 105: 724–733. 10.1016/j.biopha.2018.06.030 [DOI] [PubMed] [Google Scholar]
  • 62.Yokozawa T, Kim YJ. Piceatannol inhibits melanogenesis by its antioxidative actions. Biol Pharm Bull. 2007; 30(11): 2007–2011. 10.1248/bpb.30.2007 [DOI] [PubMed] [Google Scholar]
  • 63.Lu Y, Wang A, Shi P, Zhang H. A Theoretical Study on the Antioxidant Activity of Piceatannol and Isorhapontigenin Scavenging Nitric Oxide and Nitrogen Dioxide Radicals. PLoS One. 2017; 12(1): e0169773 10.1371/journal.pone.0169773 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Chen WJ, Du JK, Hu X, Yu Q, Li DX, Wang CN, et al. Protective effects of resveratrol on mitochondrial function in the hippocampus improves inflammation-induced depressive-like behaviour. Physiol Behav. 2017; 182: 54–61. 10.1016/j.physbeh.2017.09.024 [DOI] [PubMed] [Google Scholar]
  • 65.Xu Y, Phoon CK, Berno B, D’Souza K, Hoedt E, Zhang G, et al. Loss of protein association causes cardiolipin degradation in Barth syndrome. Nat Chem Biol. 2016; 12(8): 641–647. 10.1038/nchembio.2113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Kimbrough CW, Lakshmanan J, Matheson PJ, Woeste M, Gentile A, Benns MV, et al. Resveratrol decreases nitric oxide production by hepatocytes during inflammation. Surgery. 2015; 158(4): 1095–1101. 10.1016/j.surg.2015.07.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2008; 294(3): 478–488. 10.1152/ajplung.00361.2007 [DOI] [PubMed] [Google Scholar]
  • 68.Li XN, Ma LY, Ji H, Qin YH, Jin SS, Xu LX. Resveratrol protects against oxidative stress by activating Keap1/Nrf2 antioxidant defense system in obese-asthmatic rats. Exp Ther Med. 2018; 16(6): 4339–4348. 10.3892/etm.2018.6747 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Sawicka E, Lisowska A, Kowal P, Długosz A. The role of oxidative stress in bladder cancer. Postepy Hig Med Dosw. 2015; 69: 744–752. 10.5604/17322693.1160361 [DOI] [PubMed] [Google Scholar]
  • 70.Ooi TC, Chan KM, Sharif R. Zinc L-carnosine suppresses inflammatory responses in lipopolysaccharide-induced RAW 264.7 murine macrophages cell line via activation of Nrf2/HO-1 signaling pathway. Immunopharmacol Immunotoxicol. 2017; 39(5): 259–267. 10.1080/08923973.2017.1344987 [DOI] [PubMed] [Google Scholar]
  • 71.Thiel G, Rossler OG. Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors. Pharmacol Res. 2017; 117: 166–176. 10.1016/j.phrs.2016.12.029 [DOI] [PubMed] [Google Scholar]
  • 72.Chan KM, Hamzah R, Rahaman AA, Jong VY, Khong HY, Rajab NF, et al. The pyranoxanthone inophyllin A induces oxidative stress mediated-apoptosis in Jurkat T lymphoblastic leukemia cells. Food Chem Toxicol. 2012; 50(8):2916–2922. 10.1016/j.fct.2012.04.048 [DOI] [PubMed] [Google Scholar]
  • 73.Leong LM, Chan KM, Hamid A, Latip J, Rajab NF. Herbal formulation C168 attenuates proliferation and induces apoptosis in HCT 116 human colorectal carcinoma cells: Role of oxidative stress and DNA damage. Evid Based Complement Alternat Med. 2016; 2016(6): 1–12. 10.1155/2016/2091085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Dunlap T, Chandrasena RE, Wang Z, Sinha V, Wang Z, Thatcher GR. Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection. Chem Res Toxicol. 2007; 20(12):1903–1912. 10.1021/tx7002257 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Irina V Lebedeva

30 Jan 2020

PONE-D-19-26183

Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD-18Co human colon fibroblast cells

PLOS ONE

Dear Dr. Chan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please perform additional experiments to prove your conclusions as requested by reviewer 1.

Figures have to be modified, and the manuscript should be carefully edited by an English native speaker.

Please clarify the link between chemopreventive and cytoprotective effects of BK3C231

We would appreciate receiving your revised manuscript by Mar 15 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Irina V. Lebedeva, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

3. Please ensure that you refer to Figure 10 in your text as, if accepted, production will need this reference to link the reader to the figure.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the manuscript titled “Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD-18Co human colon fibroblast cells” Tan et al. investigate the cytoprotective role of BK3C231 on 4NQO induced damages on DNA and mitochondria were investigated in normal human colon fibroblast, CCD-18Co cells.

Authors demonstrate that BK3C231 protected normal human colon fibroblast, CCD-18Co cells. against DNA strand breaks, micronucleus formation as well as dissipation of mitochondrial membrane potential (ΔΨm) and cardiolipin induced by 4 NQO treatment. These effects seem to be ascribed to the ability of BK3C231 in causing NO downregulation as well as an increase in GSH level.

The manuscript is interesting, however authors need to provide additional clues of the mechanism described.

Major point

• Authors exclude that ROS production can play a role in 4NQO mechanism that seems, indeed, due to RNS generation as demonstrated by Griess test. To better clarify this aspect authors should report data of both ΔΨm and NO production in the presence of a positive control as a NO inhibitor, such as L-NAME.

• A more specific analysis of nitrosative stress as a consequence of an oxidative unbalance should be confirmed by an analysis focused on intracellular content of thiol groups as well as carbonylated proteins.

• To exclude the production of oxidative stress from mitochondrial environment author should explore a possible anion superoxide measuring by the fluorogenic probe MitoSox Red, also in the presence of antimycin A.

Minor points

The manuscript should carefully read a mother tongue English speaker.

Reviewer #2: Comments to the Authors

The manuscript from Huan Huan Tan et al. entitled “Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD-18Co human colon fibroblast cells” (Manuscript Number: PONE-D-19-26183) seems to be an interesting manuscript. There are points which need to be addressed.

1. There seems so many figures and each figure has only one or two graphs. Reviewers recommend authors to unite them.

2. The horizontal axis in some figures are not easy to understand; for example Figs. 4A, 4B, 5B, 6, 7, 9A, 9B, and 9C. Authors can improve them so that readers understand; for example using plus (+) and minus (-) signs.

3. Reviewers do not think the findings in this study indicate chemoprevnetive potential of BK3C231, but only cytoprotective potential. Several parts of manuscript should be changed.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 May 4;15(5):e0223344. doi: 10.1371/journal.pone.0223344.r002

Author response to Decision Letter 0


23 Mar 2020

Dear Dr. Lebedeva,

We would like to thank you and the reviewers for your insightful and constructive comments to help improve our manuscript entitled “Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD18-Co human colon fibroblast cells”.

Please kindly find our detailed responses to all the comments raised as below.

Author response to academic editor

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response to editor’s comment no.1: Manuscript has been checked thoroughly to meet PLOS ONE's style requirements.

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Response to editor’s comment no. 2: The phrase “data not shown” has been removed and we have included a table with reference to the text.

3. Please ensure that you refer to Figure 10 in your text as, if accepted, production will need this reference to link the reader to the figure.

Response to editor’s comment no. 3: Figure 10 has been changed to Figure 8 and the figure has been referred to in the revised manuscript’s text.

Author response to reviewers

Reviewer #1: In the manuscript titled “Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD-18Co human colon fibroblast cells” Tan et al. investigate the cytoprotective role of BK3C231 on 4NQO induced damages on DNA and mitochondria were investigated in normal human colon fibroblast, CCD-18Co cells.

Authors demonstrate that BK3C231 protected normal human colon fibroblast, CCD-18Co cells. against DNA strand breaks, micronucleus formation as well as dissipation of mitochondrial membrane potential (ΔΨm) and cardiolipin induced by 4NQO treatment. These effects seem to be ascribed to the ability of BK3C231 in causing NO downregulation as well as an increase in GSH level.

The manuscript is interesting, however authors need to provide additional clues of the mechanism described.

Major point

• Authors exclude that ROS production can play a role in 4NQO mechanism that seems, indeed, due to RNS generation as demonstrated by Griess test. To better clarify this aspect authors should report data of both ΔΨm and NO production in the presence of a positive control as a NO inhibitor, such as L-NAME.

Response to reviewer #1’s comment: We thank the reviewer for the suggestion. We have included resveratrol as positive control instead of L-NAME to support our findings in the revised manuscript. We use resveratrol as a positive control because resveratrol falls under the same stilbene family as BK3C231 and has been shown by several studies to protect against ΔΨm loss and inhibit NO generation (Chen et al. 2017, doi: 10.1016/j.physbeh.2017.09.024; Xu et al. 2016, doi: 10.1038/nchembio.2113; Kimbrough et al. 2015, doi: 10.1016/j.surg.2015.07.012). In this study, RV indeed protected 4NQO-treated cells against ΔΨm loss and suppressed NO generation.

• A more specific analysis of nitrosative stress as a consequence of an oxidative unbalance should be confirmed by an analysis focused on intracellular content of thiol groups as well as carbonylated proteins.

Response to reviewer #1’s comment: We have already included analysis of intracellular content of thiol groups namely glutathione (GSH) using Ellman’s reagent (Section 3.6, Figure 7C). This method is a sensitive and accurate measurement of intracellular GSH (Rahman et al. 2006, doi: 10.1038/nprot.2006.378) which contributes to specific analysis of nitrosative stress in addition to the assessment of intracellular and extracellular NO level in our study.

• To exclude the production of oxidative stress from mitochondrial environment author should explore a possible anion superoxide measuring by the fluorogenic probe MitoSox Red, also in the presence of antimycin A.

Response to reviewer #1’s comment: We acknowledged the reviewer’s suggestion to use MitoSox Red to measure mitochondrial superoxide anion, however, in this study, we have included flow cytometric assessment of superoxide anion level using HE staining and hydrogen peroxide level using DCFH-DA staining, with the inclusion of positive control for ROS generation which is hydroquinone (HQ). Both HE and DCFH-DA are ideal, widely-used probes to detect intracellular oxidant formation and they serve as sensitive, specific and direct techniques to measure the redox state of a cell regardless of the origin of ROS, whether in cytoplasm or mitochondria (Kalyanaraman et al. 2012, doi: 10.1016/j.freeradbiomed.2011.09.030; Eruslanov & Kusmartsev 2010, doi: 10.1007/978-1-60761-411-1_4). As discussed in Section 4, 4NQO is able to generate ROS directly without involvement of mitochondria, even in a cell-free system (Arima et al. 2006, doi: 10.1093/toxsci/kfj161). This prompted us to determine the role of ROS in 4NQO-induced genotoxicity and mitochondrial toxicity prior to elucidating the cytoprotective role of BK3C231. Through these assessments, our study demonstrated that there were no inductions of intracellular superoxide and hydrogen peroxide levels in 4NQO-treated cells as shown in Figure 6, leading to indication that neither cytoplasm nor mitochondria played a role in ROS production in 4NQO-treated cells. Interestingly, BK3C231 demonstrated potential as antioxidant by inhibiting HQ-induced ROS production. Therefore, we deemed these findings sufficient to fulfil one of the objectives in our study.

Minor points

The manuscript should carefully read a mother tongue English speaker.

Response to reviewer #1’s comment: The revised manuscript has been carefully edited by an English native speaker. One of our authors, Dr. Noel Thomas is an English native speaker from the United Kingdom who is currently residing in Malaysia.

Reviewer #2: Comments to the Authors

The manuscript from Huan Huan Tan et al. entitled “Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD-18Co human colon fibroblast cells” (Manuscript Number: PONE-D-19-26183) seems to be an interesting manuscript. There are points which need to be addressed.

1. There seems so many figures and each figure has only one or two graphs. Reviewers recommend authors to unite them.

Response to reviewer #2’s comment: We thank the reviewer for the recommendation. Some of the figures have been united in the revised manuscript.

2. The horizontal axis in some figures are not easy to understand; for example Figs. 4A, 4B, 5B, 6, 7, 9A, 9B, and 9C. Authors can improve them so that readers understand; for example using plus (+) and minus (-) signs.

Response to reviewer #2’s comment: The horizontal axis especially in the mentioned figures have been revised for better understanding to readers.

3. Reviewers do not think the findings in this study indicate chemopreventive potential of BK3C231, but only cytoprotective potential. Several parts of manuscript should be changed.

Response to reviewer #2’s comment: We agree with the reviewer and certain parts of the manuscript have been changed and rephrased to indicate BK3C231’s cytoprotective potential. Cytoprotection contributes as one of the steps in chemoprevention by suppressing the initiation stage of carcinogenesis caused by carcinogen-induced cellular damages on DNA and mitochondria. This study has demonstrated the cytoprotective role of BK3C231 and therefore warrants further investigation on BK3C231’s chemopreventive potential in the near future.

We hope that you find the paper acceptable for publication in PLOS ONE. We look forward to hearing from you soon.

Thank you.

Kind regards,

Chan Kok Meng

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Irina V Lebedeva

16 Apr 2020

Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD-18Co human colon fibroblast cells

PONE-D-19-26183R1

Dear Dr. Chan,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Irina V. Lebedeva, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: Comments to the Authors

According to the comments from the Reviewers, the Authors responded adequately and conducted several modifications appropriately. This seems a quite well-written and reshaped manuscript. Therefore, this can be suitable for publication in the journal.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

Irina V Lebedeva

22 Apr 2020

PONE-D-19-26183R1

Cytoprotective effects of (E)-N-(2-(3, 5-dimethoxystyryl) phenyl) furan-2-carboxamide (BK3C231) against 4-nitroquinoline 1-oxide-induced damage in CCD-18Co human colon fibroblast cells

Dear Dr. Chan:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Irina V. Lebedeva

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES